clinical endpoint raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-21 and is reviewed periodically as new material appears.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C129H215N33O55 | Calculated for the acetylated 28-residue peptide |
| Appearance | White to off-white powder | Lyophilized solid recovered from aqueous buffer |
| Solubility | Freely soluble in water | Typically dissolved in water or buffer before use |
| Typical storage | -20 C or below, desiccated | Protect from light and avoid repeated freeze-thaw cycles |
| Identity testing | Reverse-phase HPLC with mass spectrometry | Retention time and measured mass confirm the sequence |
The lyophilized peptide is generally stable for extended periods when kept cold and dry. Once dissolved, aqueous solutions are less stable; hydrolysis, oxidation, and aggregation can degrade the material. Storage at -20 °C or lower slows these processes. Repeated freeze-thaw cycles are best avoided because they can promote aggregation. The exact shelf life depends on formulation, pH, and concentration, so stability studies are typically performed for each specific product.
Quality control for thymosin alpha-1 focuses on identity, purity, and potency. Identity is confirmed by mass spectrometry and amino acid analysis, while purity is assessed by chromatography with limits on related substances and residual solvents. Potency assays may use cell-based immune readouts, but these are not standardized across laboratories. Regulatory status differs by jurisdiction; no product is approved in the United States for clinical use, whereas some other countries register injectable forms for specific indications.
Quantifying thymosin alpha-1 in a sample usually relies on reverse-phase high-performance liquid chromatography. The peptide lacks strong chromophores, so detection often occurs at 214 nm, where the peptide backbone absorbs. Mass spectrometry provides confirmatory identification and can detect sequence variants or truncations. Immunoassays have been used in biological matrices, but they may cross-react with related fragments. For purity assessment, chromatographic peak area gives the main component percentage, while mass accuracy verifies molecular identity.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Outside the cell, LTC4 can be converted by ubiquitous enzymes to form successively LTD4 and LTE4, which retain biological activity. The cysteinyl-leukotrienes act at their cell-surface receptors CysLT1 and CysLT2 on target cells to contract bronchial and vascular smooth muscle, to increase permeability of small blood vessels, to enhance secretion of mucus in the airway and gut, and to recruit leukocytes to sites of inflammation. Both LTB4 and the cysteinyl-leukotrienes (LTC4, LTD4, LTE4) are partly degraded in local tissues, and ultimately become inactive metabolites in the liver.
=== Central nervous system and appetite regulation === Semaglutide crosses the blood-brain barrier to interact with the arcuate nucleus of the hypothalamus, a crucial brain region for energy balance. It suppresses appetite through a dual mechanism involving hypothalamic feeding circuits. Acute administration has been shown to stimulate anorexigenic (satiety-inducing) neurons that express proopiomelanocortin (POMC) and cocaine-and amphetamine-regulated transcript (CART), while simultaneously inhibiting orexigenic (appetite-inducing) neurons that express AgRP and NPY. However, more recent evidence indicates that during chronic treatment, AgRP neurons become functionally recruited and are required for the full weight-lowering effects of GLP-1 receptor agonists in female mice, despite persistent suppression of food intake. This recruitment is associated with increased neuronal activation, synaptic remodeling, and fat utilization, suggesting that AgRP neurons contribute to the adaptive metabolic responses that sustain long-term weight loss rather than simply promoting hunger. Furthermore, semaglutide improves the brain's sensitivity to leptin, a hormone produced by fat cells that signals satiety to the brain. In individuals with obesity, chronic low-grade inflammation often leads to "leptin resistance"—a pathological state where circulating leptin levels are high, but the brain fails to register the signal, leading to persistent hunger. Semaglutide counteracts this resistance by downregulating inhibitory proteins like SOCS3 and PTP1B.
Scott Tanner is a Canadian scientist, inventor, and entrepreneur. His areas of expertise include mass spectroscopy, especially inductively coupled plasma mass spectrometry (ICP-MS), and mass cytometry. Tanner is best known for his work on the fundamentals of inductively coupled plasma mass spectrometry, for the invention of mass cytometry, and co-founding (with Dmitry Bandura, Vladimir Baranov and Olga Ornatsky) DVS Sciences in 2004,(acquired by Fluidigm in 2014 and then renamed to Standard BioTools in 2022) the company that first commercialized the instrument and reagents of mass cytometry.
Sources: en.wikipedia.org
==== Melt spinning ==== Melt-spinning is a cost-effective method widely used in the textile industry for producing polymeric fibers without solvents. However, its application in biostructures is limited due to factors such as polymer decomposition at lower temperatures, inadequate control over melt temperature during spinning, and challenges in controlling the final fiber structure. In this process, polymer granules are melted in an extruder to form a spinning dope, then extruded through a spinneret and rapidly cooled to solidify the filament. Despite its drawbacks, melt-spinning of biopolymers has been explored for various bio-applications. The use of bio-based reinforcements is being investigated as a solution to overcome challenges associated with producing biotextiles via melt-spinning.
== History == In March 2007, Eatza Pizza was bought by International Franchise Associates. Following the purchase, the corporate headquarters was moved from Arizona to Westport, Connecticut. In July 2008, International Franchise Associates filed for Chapter 7 bankruptcy. At that time, only five Eatza Pizza locations were left.
Livagen is a tetrapeptide with the sequence KEDA or Lys-Glu-Asp-Ala. It is one of a number of small peptides developed in Russia in the late 1990s and early 2000s which have antiinflammatory and purported anti-aging effects, and are now widely sold over the internet as anti-aging products though with relatively limited evidence to support these claims.
1991: Doris Malkin Curtis became the first female president of the Geological Society of America. 1991: Indian geologist Sudipta Sengupta became the first female scientist to receive the Shanti Swaroop Bhatnagar Award in the Earth Sciences category. 1991; British chemist and cosmonaut Helen Patricia Sharman became the first woman to visit the Mir space station in May 1991. 1992: American engineer, physician, and NASA astronaut Mae Carol Jemison became the first black woman to travel into space when she served as a mission specialist aboard the Space Shuttle Endeavour. Jemison joined NASA's astronaut corps in 1987 and was selected to serve for the STS-47 mission, during which she orbited the Earth for nearly eight days on September 12–20, 1992. 1992: American chemist Edith M. Flanigen became the first woman awarded the Perkin Medal (widely considered the highest honor in American industrial chemistry) for her outstanding achievements in applied chemistry. The medal especially recognized her syntheses of aluminophosphate and silicoaluminophosphate molecular sieves as new classes of materials. 1993: American molecular biologist and biogerontologist Cynthia Kenyon discovered that a single-gene mutation (Daf-2) could double the lifespan of C. elegans, and that this could be reversed by a second mutation in daf-16m. 1995: German biologist Christiane Nüsslein-Volhard received the Nobel Prize in Physiology or Medicine, shared with Edward B. Lewis and Eric F. Wieschaus, "for their discoveries concerning the genetic control of early embryonic development".
Sources: en.wikipedia.org
== Examples == Eisenin (pGlu-Gln-Ala-OH) is a peptide with immunological activity that is isolated from the Japanese marine alga (Eisenia bicyclis) which more commonly is known as Arame KPV tripeptide (Pro-Val-Lys) has antiinflammatory effects and is used in skincare products. GHK-Cu (glycyl-L-histidyl-L-lysine) is a human copper binding peptide with wound healing and skin remodeling activity, which is used in anti-aging cosmetics and more commonly referred to as copper peptide Lactotripeptides (Ile-Pro-Pro and Val-Pro-Pro) found in milk products, act as ACE inhibitors Leupeptin (N-acetyl-L-leucyl-L-leucyl-L-argininal) is a protease inhibitor that also acts as an inhibitor of calpain Melanostatin (prolyl-leucyl-glycinamide) is a peptide hormone produced in the hypothalamus that inhibits the release of melanocyte-stimulating hormone (MSH) Ophthalmic acid (L-γ-glutamyl-L-α-aminobutyryl-glycine) is an analogue of glutathione isolated from crystalline lens Norophthalmic acid (y-glutamyl-alanyl-glycine) is an analogue of glutathione (L-cysteine replaced by L-alanine) isolated from crystalline lens Thyrotropin-releasing hormone (TRH, thyroliberin or protirelin) (L-pyroglutamyl-L-histidinyl-L-prolinamide) is a peptide hormone that stimulates the release of thyroid-stimulating hormone and prolactin by the anterior pituitary ACV (δ-(L-α-aminoadipyl)-L-Cys-D-Val) is a key biosynthetic precursor to penicillin and cephalosporin. Vesugen (Lys-Glu-Asp) Pinealon (Glu-Asp-Arg) Chonluten (Glu-Asp-Gly) PGP (Pro-Gly-Pro) a neutrophil chemoattractant. Glycyl-prolyl-hydroxyproline (Gly-Pro-Hyp)
=== Contraindications === Pregnancy is an absolute contraindication as with most other vitamin A products, it should also be avoided when it comes to systemic use in any women that is of childbearing potential and not taking precautions to prevent pregnancy. Toctino (the oral capsule formulation of alitretinoin) contains soya oil and sorbitol. Patients who are allergic to peanut, soya or with rare hereditary fructose intolerance should not take this medicine. It is also contraindicated in nursing mothers. The oral formulation of alitretinoin is contraindicated in patients with:
This results in generalized inflammation in the heart, producing acute erosions and vegetations with fibrin deposition in the mitral valve that may be followed by chronic changes over years to decades, including shortening of the chordae tendinae and thickening or fusion of the mitral leaflets, leading to a severely compromised "buttonhole" or "fish mouth" valve. In 70% of cases rheumatic heart disease involves only the mitral valve, while 25% of cases involve both the aortic and mitral valves. Involvement of other heart valves without damage to the mitral is exceedingly rare. Mitral stenosis is almost always caused by rheumatic heart disease. Less than 10% of aortic stenosis is caused by rheumatic heart disease. Rheumatic fever can also cause chronic mitral and aortic regurgitation. While developed countries once had a significant burden of rheumatic fever and rheumatic heart disease, medical advances and improved social conditions have dramatically reduced their incidence. Many developing countries, as well as indigenous populations within developed countries, still carry a significant burden of rheumatic fever and rheumatic heart disease and there has been a resurgence in efforts to eradicate the diseases in these populations. Among persons who have experienced rheumatic fever, long-term intramuscular antibiotic therapy is used as secondary prophylaxis against additional streptococcal infections, which can contribute to progression of rheumatic heart disease.
Sources: en.wikipedia.org
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.
No. The two peptides share part of a name but differ in length, sequence, and net charge. Literature searches that treat them as one compound return misleading results.
Solid-phase peptide synthesis is the usual route, and recombinant expression has also been described. Both approaches produce material matching the natural sequence.
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.